Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sebelius Draws Parallels Between Her State Experience And HHS Tasks Ahead

Executive Summary

Over the course of two non-contentious hearings to discuss her nomination as HHS secretary, Kansas governor Kathleen Sebelius drew many comparisons between some of the tasks envisioned through health care reform and her work at the state level

You may also be interested in...



Part D Issues, Medicaid Drug Rebates On Minds Of Senate Finance Members

Senate Finance Committee members revealed in their written questions to HHS Secretary-designate Kathleen Sebelius concerns across a wide range of issues, including Medicaid drug rebates and Medicare Part D, that could come to the forefront during the upcoming health care reform debate

Part D Issues, Medicaid Drug Rebates On Minds Of Senate Finance Members

Senate Finance Committee members revealed in their written questions to HHS Secretary-designate Kathleen Sebelius concerns across a wide range of issues, including Medicaid drug rebates and Medicare Part D, that could come to the forefront during the upcoming health care reform debate

Health IT Not “Low-Hanging Fruit” In Health Reform, Some Experts Say

Despite President Barack Obama and others calling health information technology "low-hanging fruit" in the context of comprehensive health care reform, some IT experts and even some in government see it as a more complex problem to solve

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel